Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01285765
Recruitment Status : Active, not recruiting
First Posted : January 28, 2011
Last Update Posted : March 6, 2018
CHU de Nancy
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2020
  Estimated Study Completion Date : December 2020